At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Ofatumumab 100 +3 moredrug
Likely dose
Ofatumumab 100 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
In Brief
A Phase 2 clinical trial evaluating Ofatumumab 100, Ofatumumab 300, and 2 other interventions for Multiple Sclerosis. Completed, enrolled 38 participants.
Detailed Summary
The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or Immunoglobulin G (IgG) levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartMay 2008
Primary CompletionMay 2010
Study CompletionOct 2011
TodayJul 2026
First PostedMar 21, 2008
Enrollment StartMay 1, 2008
Primary CompletionMay 1, 2010
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.3 years ago
Interventions
Ofatumumab 100drug
100mg
Ofatumumab 300drug
300mg
Ofatumumab 700drug
700mg
Placebodrug
matching placebo